KLBF — Strategic partnership for cancer therapy technology

KLBF — Strategic partnership for cancer therapy technology Kalbe Farma (KLBF), through its subsidiary Bifarma Adiluhung, has entered a technology transfer and licensing agreement with South Korea's GC Cell to accelerate access to Immuncell-LC, an innovative cell therapy for cancer treatment in Indonesia. This partnership focuses on using Immuncell-LC, a T-cell therapy for solid tumors, particularly liver cancer. KLBF expects this collaboration to improve cancer treatment availability in Indonesia and enhance patient care. Note that, KLBF reported a net profit increase of 18.42% yoy to IDR1.80 tn in 1H24. (Source : Kontan)